GSK Longstanding Legacy & Lasting Leadership in BENLYSTA Commercialization

​​Sheri Mullen, Senior Vice President, Specialty Business Unit, US Pharma at GSK discusses BENLYSTA (belimumab), the first and only biologic approved for lupus and lupus nephritis in adults, and its decade-in-market milestone. She shares insights around GSK leadership in reducing progression of long-term organ damage with BENLYSTA’s proven efficacy, investing in comprehensive lupus programs and clinical trials, revolutionizing the stagnant lupus landscape, and engaging lupus patient and advocacy communities to build trust and gain insights to better understand patient and caregiver needs and more.

Sheri Mullen, Senior Vice President, Specialty Business Unit, US Pharma

Since 2018, Sheri has built and led GSK’s U.S. Specialty Pharmaceuticals business. She is responsible for leading, developing and managing the strategic and financial performance of the commercial organization. Currently, the team is made up of more than 500 professionals accountable for commercializing BENLYSTA, the first biologic approved for lupus in more than 50 years and NUCALA, the first biologic approved for severe eosinophilic asthma. A dedicated professional with more than 30 years experience, Sheri has held various roles with increasing responsibility in sales, marketing, and operations. ​She also serves as a Global Executive Sponsor of the Women’s Leadership Initiative (WLI), an award-winning professional group committed to accelerating gender parity and to helping GSK be a modern employer.